IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN MULTIPLE RECALL/REFRACTORY MYELOMA (MMRR): ANALYSIS OF HIGH-RISK PATIENT SUBGROUPS (PTS) FROM THE KARMMA STUDY

被引：0
|
作者：
Jesus, San-Miguel [1 ]
Noopur, Raje S. [2 ]
David, Siegel [3 ]
Sundar, Jagannath [4 ]
Sagar, Lonial [5 ]
Nikhil, Munshi C. [6 ,7 ]
Philippe, Moreau [8 ]
Hartmut, Goldschmidt [9 ,10 ]
Michele, Cavo [11 ]
Anna, Truppel-Hartmann [12 ]
Everton, Rowe [13 ]
Huang Liping [13 ]
Amit, Agarwal [13 ]
Julie, Wang [13 ]
Timothy, Campbell B. [13 ]
Donna, Reece E. [14 ]
机构：
[1] Clin Univ Navarra, Pamplona, Spain
[2] Hosp Gen Massachusetts, Boston, MA 02114 USA
[3] Ctr Med Univ Hackensack, Hackensack, NJ USA
[4] Mt Sinai Hosp, New York, NY 10029 USA
[5] Escuela Med Emory, Atlanta, GA USA
[6] Harvard Med Sch, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA
[7] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
[8] Ctr Hosp Univ Nantes, Nantes, France
[9] Hosp Univ Heidelberg, Heidelberg, Germany
[10] Natl Ctr Tumor Dis, Heidelberg, Germany
[11] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy
[12] Bluebird Bio, Cambridge, MA USA
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Ctr Oncol Princess Margaret, Toronto, ON, Canada
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO-069
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [41] EVALUATION OF HEALTH STATUS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), CAR T CELL THERAPY AGAINST BCMA
    Paula, Rodriguez-Otero
    Michel, Delforge
    Nina, Shah
    Parames-Waran, Hari
    Julia, Braverman
    Andrew, Trigg
    Payal, Patel
    Liping, Huang
    Kristen, Hege
    Sujith, Dhanasiri
    HAEMATOLOGICA, 2021, 106 (10) : 287 - 288
  • [42] The BCMA CAR T cell therapy idecabtagene vicleucel (ide-cel/bb2121) in relapsed and refractory multiple myeloma (RRMM): outcomes from phase 1 study support the phase 3 KarMMa-3 study design to compare ide-cel versus standard triplet regimens
    Einsele, H.
    Raab, M.
    Kroeger, N.
    Fenk, R.
    Scheid, C.
    Munshi, N.
    Petrocca, F.
    Hege, K.
    Novick, S.
    Raje, N.
    Kochenderfer, J. N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 140 - 141
  • [43] Estimation of Long-Term Post-Infusion Costs of Care for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Following Administration of Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial
    McGarvey, November
    Carattini, Thomas
    Ung, Brian
    Campbell, Timothy B.
    Imanak, Ken
    Patwardhan, Pallavi
    BLOOD, 2022, 140 : 10947 - 10948
  • [44] Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor plus dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma
    Rodriguez-Otero, Paula
    Ayers, Dieter
    Cope, Shannon
    Davies, Faith E.
    Delforge, Michel
    Mojebi, Ali
    Jansen, Jeroen P.
    Weisel, Katja
    Hege, Kristen
    Dhanasiri, Sujith
    LEUKEMIA & LYMPHOMA, 2021, 62 (10) : 2482 - 2491
  • [45] Results from the KarMMa clinical trial: Secondary Quality-of-Life domains in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with the BCMA-directed CAR T cell therapy Idecabtagene Vicleucel (ide-cel; bb2121)
    Einsele, H.
    Shah, N.
    Delforge, M.
    San-Miguel, J. F.
    Bertin, K. B.
    Tahir, M. J.
    Lewis, H. B.
    Wang, J.
    Braverman, J.
    Campbell, T. B.
    Dhanda, D.
    Munshi, N. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 206 - 208
  • [46] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy: Qualitative analyses of pretreatment patient interviews in the KarMMa trial.
    Braverman, Julia
    Moshkovich, Olga
    Miera, Matthew
    Shah, Selam
    Brion, Triza
    Devlen, Jennifer
    Hege, Kristen
    Campbell, Timothy Brandon
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [47] Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups
    Patel, Krina
    Rodriguez-Otero, Paula
    Manier, Salomon
    Baz, Rachid
    Raab, Mark-Steffen
    Cavo, Michele
    Callander, Natalie
    Costa, Luciano J.
    Moreau, Phillippe
    Solomon, Scott
    Chen, Christine
    Raje, Noopur
    Scheid, Christoph
    Delforge, Michel
    Larsen, Jeremy
    Pabst, Thomas
    Suzuki, Kenshi
    Truppel-Hartmann, Anna
    Yang, Zhihong
    Piasecki, Julia
    Felten, Jasper
    Caia, Andrea
    Cook, Mark
    Giralt, Sergio
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S498
  • [48] Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial
    Shah, Nina
    Delforge, Michel
    San-Miguel, Jesus F.
    Bertin, Kaitlyn B.
    Tahir, Muna J.
    Lewis, Hannah B.
    Wang, Julie
    Braverman, Julia
    Campbell, Timothy B.
    Dhanda, Devender
    Munshi, Nikhil C.
    BLOOD, 2020, 136
  • [49] KarMMa Subanalysis: Correlation of Baseline Characteristics with Complete Response (CR) to Idecabtagene vicleucel (Ide-Cel, bb2121), a BCMA-Targeted CAR-T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
    Einsele, H.
    Shah, N.
    Munshi, N.
    Berdeja, J.
    Jagannath, S.
    Finney, O.
    Martin, N.
    Agarwal, A.
    Rowe, E.
    Campbell, T. B.
    San-Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 248 - 248
  • [50] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY: QUALITATIVE ANALYSES OF EARLY POST-TREATMENT INTERVIEWS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS IN THE KARMMA CLINICAL TRIAL
    Braverman, J.
    Dhanda, D. S.
    Moshkovich, O.
    Lanar, S.
    Miera, M.
    Williams, A. E.
    Murphy, R.
    Devlen, J.
    Hege, K.
    Campbell, T. B.
    VALUE IN HEALTH, 2021, 24 : S61 - S61
12345